Dr. Fedyanin on Future Treatment Landscape of CRC

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

There will hopefully be more novel agents approved in the CRC space, Fedyanin explains, such as combination regimens of MEK inhibitors and PD-1 inhibitors. Additionally, he predicts and anticipates more research dedicated to treatments for patients with CRC who harbor KRAS mutations. Currently, there are a lack of effective agents able to target this patient population.